In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has announced an exclusive licensing agreement with LaNova Medicines Ltd., a Shanghai-based biotech company. This agreement grants Merck the global rights to develop, manufacture, and commercialize LM-299, an investigational bispecific antibody […]
Merck & Co., a global leader in pharmaceuticals, has acquired Modifi Biosciences, a cutting-edge biotech startup based in New Haven, Connecticut, for up to $1.3 billion. The agreement, which involves an upfront payment of $30 million, includes milestone-dependent payouts that could total over a billion dollars. This acquisition marks Merck’s latest move to expand its […]
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating the efficacy of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy by Merck, combined with LENVIMA (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor […]
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination with enfortumab vedotin for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) who have not received prior systemic therapy for this condition. This decision […]
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an exclusive global license for opevesostat (MK-5684/ODM-208) and other CYP11A1 targeting candidates, following a mutual agreement with Orion Corporation. This pivotal deal marks a significant advancement in the treatment of prostate […]
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire EyeBio Limited, a prominent ophthalmology-focused biotechnology company, in a deal worth up to $3 billion. This acquisition includes an upfront payment of $1.3 billion in cash, with additional developmental, regulatory, and commercial milestone payments […]
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, South Korea. This initiative stands as the most significant investment by Merck’s Life Science business sector in the Asia-Pacific region to date, underscoring the company’s dedication to expanding its operations […]
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, Merck’s innovative anti-PD-1 therapy, significantly reduces the risk of death by 38% compared to placebo, marking a milestone in adjuvant therapy for patients with renal cell carcinoma (RCC) post-nephrectomy. Presented […]
Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its anti-PD-1 therapy. This approval, in combination with chemoradiotherapy (CRT), is for the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA cervical cancer. The approval […]
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) have entered a definitive agreement where Merck will acquire Harpoon for $23 per share in cash, totaling an approximate equity value of $680 million. This strategic acquisition aims to bolster Merck’s oncology pipeline with Harpoon’s advanced cancer […]